UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~ 21December 10, 2019

FIBROCELL SCIENCE, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE	001-31564	87-0458888
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

405 EAGLEVIEW BLVD., EXTON, PA 19341

(Address of principal executive offices and zip code)

(484) 713-6000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	FCSC	The Nasdaq Stock Market LLC

Indicate by check mark whether the ~~registrant~~ registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨ o

If an emerging growth company, indicate by by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ o

Item 85.0107. ~~Other~~Submission ~~Events~~of Matters to a Vote of Security Holders.

~~On November 21, 2019,~~ Fibrocell Science, Inc., ~~a Delaware corporation~~ (the “Company”), held ~~mailed~~a ~~notices~~special tomeeting ~~the~~of ~~holders~~stockholders ofon ~~its~~December ~~outstanding~~10, ~~classes~~2019 of(the ~~Series~~“special Ameeting”). At ~~Convertible~~the ~~Preferred~~special ~~Stock~~meeting, ~~convertible~~the ~~promissory~~Company’s ~~notes~~stockholders ~~and~~approved ~~common~~the ~~stock~~two ~~warrants,~~proposals asdescribed ~~required~~below. Stockholder byaction ~~the~~on ~~terms~~a ofthird ~~such securities~~proposal, ~~stating~~to ~~that~~approve one ~~the~~or ~~Company~~more ~~expects the~~adjournments ~~closing~~ of the ~~previously~~special ~~announced~~meeting, ~~merger~~if ofnecessary ~~the~~or ~~Company~~appropriate, ~~with~~to ~~Castle~~solicit ~~Creek~~additional ~~Merger~~proxies ~~Corp.,~~if athere ~~subsidiary~~are ofnot ~~Castle~~sufficient votes ~~Creek~~to ~~Pharmaceutical Holdings,~~approve ~~Inc.~~proposal 1, towas ~~occur~~not onrequired ~~December~~and ~~13,~~no ~~2019~~vote was taken on that proposal.

~~Forward-Looking~~The ~~Statements~~final voting results with respect to each proposal voted upon at the special meeting are set forth below.

~~This~~Proposal current report, and any documents to which the Company refers you in this communication, contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often include the words “anticipates,” “expect,” “believe,” “will,” “intend,” “plan,” and words of similar substance. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or performance to differ materially from those expressed in or contemplated by the forward-looking statements, including the following (i) the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the Company’s business and the price of the Company’s common stock, (ii) the failure to satisfy any of the conditions to the consummation of the proposed transaction, including without limitation, obtaining stockholder approval, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, (iv) the outcome of any legal proceedings that have been or may be instituted against the Company related to the Merger Agreement or the proposed transaction and (v) other risks described in the Company’s filings with the SEC, such as its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update or revise publicly the information in this communication, whether as a result of new information, future events or otherwise, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.1

~~SIGNATURES~~The Company’s stockholders adopted the Agreement and Plan of Merger, dated as of September 12, 2019 (the “Merger Agreement”), by and among the Company, Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Castle Creek”) and Castle Creek Merger Corp., a Delaware corporation and a wholly-owned subsidiary of Castle Creek (“Merger Sub”), as it may be amended from time to time, pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Castle Creek (the “Merger”), and holders of common stock, par value $0.001 per share, of the Company (“Common Stock”) will be entitled to receive $3.00 in cash, without interest and less any applicable withholding taxes, for each share of Common Stock that they own immediately prior to the effective time of the Merger, as set forth below:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

For		Against		Abstentions		Broker Non-Votes
6,980,096		35,825		7,228		0

~~Fibrocell~~Proposal ~~Science, Inc. By: /s/ John M. Maslowski John M. Maslowski President and Chief Executive Officer~~2

~~Date:~~The ~~November~~Company’s 21stockholders approved, on ~~2019~~a non-binding, advisory basis, the compensation that will or may become payable to the Company’s named executive officers in connection with the Merger, as set forth below:

For		Against		Abstentions		Broker Non-Votes
6,884,515		93,610		45,024		0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

		Fibrocell Science, Inc.

	By:	/s/ John M. Maslowski
		John M. Maslowski
		President and Chief Executive Officer

Date: December 10, 2019

Filing Compare · Fibrocell Science, Inc.